Caplin Point Prescribes Profits: ₹3 Dividend and Q4 Earnings Surge!

Unknown Apr 02, 2026 1,300 Views

Caplin Point Laboratories Ltd declared a dividend of ₹3 per share after reporting strong March quarter (Q4 FY25) financial results, with further growth in revenue and profitability. Caplin Point Laboratories, a prominent Indian pharma firm with a wide presence in emerging economies...

Caplin Point Laboratories Ltd declared a dividend of ₹3 per share after reporting strong March quarter (Q4 FY25) financial results, with further growth in revenue and profitability.

Caplin Point Laboratories, a prominent Indian pharma firm with a wide presence in emerging economies, posted its March 2025 quarter financial results. The firm has also announced a dividend of ₹3 per share, indicating its robust earnings and focus on shareholder payouts.

Dividend Announcement

The Board of Directors has approved a dividend payment of ₹3 per share for the year 2024-25.
This dividend payment comes on the back of a steady history of rewarding shareholders, with equally sized payouts in earlier quarters and years.

Financial Performance: March Quarter (Q4 FY25)

Consolidated Revenue: Consolidated revenue from operations was reported by the company at ₹5.02 billion (₹502 crore) for the quarter ended March 2025.
Net Profit: Consolidated net profit was at ₹1.43 billion (₹143 crore) for the same period.
Year-on-Year Growth: The company has posted double-digit growth in revenue and net profit over the last year, maintaining its growth trend.

Business Highlights

Caplin Point Laboratories continues to consolidate its leadership in Latin America, Africa, and other emerging markets through cost-effective pharmaceutical formulations and injectables.
The strong financial performance of the company and consistent dividend distribution reflect its operating efficiency and shareholder orientation.

Board Meeting and Future Outlook

The May 15, 2025, Board meeting approved the audited financial performance and the declaration of interim dividend for FY 2024-25.

Caplin Point Laboratories continues to focus on enlarging its market share and providing steady financial performance.

Sources: Moneycontrol, Kotak Securities, AlphaStreet, INDmoney, Business Standard, BlinkX Board Meeting Announcement

Stay Ahead – Explore Now! SpiceJet Payment Default Notices Issued by Two Aircraft Lessors